Hemorrhagic Fever With Renal Failure Syndrome Medication

  • Author: Rajendra Bhimma, MB, ChB, MD, DCH (SA), FCP (Paeds)(SA), MMed (Natal); Chief Editor: Craig B Langman, MD   more...
 
Updated: May 7, 2010
 

Medication Summary

Antihypertensive agents, vasoactive drugs, colloids, or diuretics may be needed to control hypertension, to treat shock, or to induce diuresis, respectively. Antibiotics have not had any benefit during the course of illness. Although intravenous ribavirin initiated within 4 days of illness reduces the morbidity and mortality associated with the disease, in the setting of adequate supportive measures and dialysis, ribavirin is not needed; at present, it is not approved for use in United States.

Next

Antihypertensive agents

Class Summary

These agents are used to treat hypertension. Pharmacotherapy may include numerous drug classes that have antihypertensive effects, such as beta-blockers, calcium-channel blockers, ACE inhibitors, alpha-blockers, and angiotensin II–receptor antagonists. The antihypertensive regimen is customized to the population, with attention on ways to enhance compliance and to improve the patient's ability to tolerate treatment. For additional information see the eMedicine pediatric topic Hypertension.

View full drug information

Nifedipine (Adalat, Procardia)

 

Relaxes coronary smooth muscle, produces coronary vasodilation and improves myocardial oxygen delivery. Sublingual administration generally safe despite theoretic concerns.

View full drug information

Atenolol (Tenormin)

 

Selectively blocks beta1-receptors with little or no effect on beta2 types.

View full drug information

Captopril (Capoten)

 

Prevents conversion of angiotensin I to angiotensin II, potent vasoconstrictor, lowering aldosterone secretion.

Previous
Next

Diuretic agents

Class Summary

These agents are used for the treatment of hypertension, oliguria, or edema. They promote the excretion of water and electrolytes by the kidneys. Diuretics are also used to treat heart failure or hepatic, renal, or pulmonary disease when sodium and water retention has resulted in edema or ascites. They may be used as monotherapy or combination to treat hypertension.

View full drug information

Furosemide (Lasix)

 

Increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Individualize dose. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after previous dose, until desired diuresis occurs. In infants, titrate with 1-mg/kg/dose increments until satisfactory effect achieved.

Previous
Next

Colloids

Class Summary

These agents are used for volume expansion to treat shock. They are preferred over crystalloids because the excessive administration of fluids can lead to extravasation caused by vascular leak, especially during the febrile and hypotensive stages.

View full drug information

Albumin (Albuminar, Albunex, Albumisol, Buminate, Albutein)

 

For certain types of shock or impending shock. Useful for plasma volume expansion and maintenance of cardiac output. Although theoretically attractive, benefit of colloid resuscitation over isotonic crystalloids not proven.

Previous
Next

Vasopressors

Class Summary

Vasopressors are used for the treatment of hypotension. Dopamine is unique among other catecholamines; unlike norepinephrine, epinephrine, and isoproterenol, low doses of dopamine increase renal blood flow without increasing the patient's heart rate or systemic arterial pressure. It is an effective vasopressor for treating shock and hypotension in persons unresponsive to plasma volume expansion (ie, crystalloids or colloids). It also dilates the mesenteric and renal blood vessels, which improves renal blood flow and increases the glomerular filtration rate, sodium excretion, and urine output. However, dosages of more than 20 mcg/kg/min may decrease renal blood flow secondary to a reversal of the dopaminergic vasodilation.

View full drug information

Dopamine (Intropin)

 

Stimulates both adrenergic and dopaminergic receptors. Hemodynamic effect depends on dose. Low doses predominantly stimulate dopaminergic receptors, which, in turn, produce renal and mesenteric vasodilation. High doses produce cardiac stimulation and renal vasodilation. After initiating therapy, increase by 1-4 mcg/kg/min q10-30min until optimal response obtained. Maintenance at < 20 mcg/kg/min satisfactory in >50% of patients.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Rajendra Bhimma, MB, ChB, MD, DCH (SA), FCP (Paeds)(SA), MMed (Natal)  Associate Professor of Pediatrics, Principal Specialist, Department of Pediatrics and Child Health, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa

Rajendra Bhimma, MB, ChB, MD, DCH (SA), FCP (Paeds)(SA), MMed (Natal) is a member of the following medical societies: American Association for the Advancement of Science, International Pediatric Transplant Association, International Society of Nephrology, South African Medical Association, South African Paediatric Association, and South African Transplant Society

Disclosure: Nothing to disclose.

Coauthor(s)

Vellore K Sairam, MBBS  Assistant Professor, Department of Nephrology, Sri Ramachandra Medical College and Research Institute, India

Disclosure: Nothing to disclose.

Luther Travis, MD  William W Glauser Professor of Pediatrics and Pediatric Nephrology, Department of Pediatrics, Divisions of Nephrology and Diabetes, University of Texas Medical Branch and Children's Hospital

Luther Travis, MD is a member of the following medical societies: Alpha Omega Alpha, American Federation for Medical Research, International Society of Nephrology, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Deogracias Pena, MD  Medical Director of Dialysis, Department of Pediatrics, Cook Children's Medical Center; Clinical Associate Professor, Texas Tech University School of Medicine

Deogracias Pena, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and American Society of Pediatric Nephrology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Frederick J Kaskel, MD, PhD  Director of the Division and Training Program in Pediatric Nephrology, Vice Chair, Department of Pediatrics, Montefiore Medical Center and Albert Einstein School of Medicine

Frederick J Kaskel, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Pediatric Society, American Physiological Society, American Society of Nephrology, American Society of Pediatric Nephrology, American Society of Transplantation, Eastern Society for Pediatric Research, Federation of American Societies for Experimental Biology, International Society of Nephrology, National Kidney Foundation, New York Academy of Sciences, Renal Physicians Association, Sigma Xi, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Howard Trachtman, MD  Program Director, Pediatrics Research, Schneider Children's Hospital, Department of Pediatrics, Division of Nephrology, Professor, Albert Einstein College of Medicine

Howard Trachtman, MD is a member of the following medical societies: American Society of Hypertension, American Society of Nephrology, American Society of Pediatric Nephrology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD  The Isaac A Abt, MD, Professor of Kidney Diseases, Feinberg School of Medicine, Northwestern University; Division Head of Kidney Diseases, Children's Memorial Hospital, Chicago

Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, and International Society of Nephrology

Disclosure: Amgen Grant/research funds None; Genzyme Grant/research funds None; Merck Grant/research funds None; NIH Grant/research funds None; Raptor Pharmaceuticals, Inc Grant/research funds None; Alexion Pharmaceuticals, Inc. Grant/research funds None

References

  1. Ahlm C, Settergren B, Gothefors L, Juto P. Nephropathia epidemica (hemorrhagic fever with renal syndrome) in children: clinical characteristics. Pediatr Infect Dis J. Jan 1994;13(1):45-9. [Medline].

  2. Ko KW. Haemorrhagic fever with renal syndrome: clinical aspects. Pediatr Nephrol. Mar 1992;6(2):197-200. [Medline].

  3. Clement J, Vercauteren J, Verstraeten WW, Ducoffre G, Barrios JM, Vandamme AM. Relating increasing hantavirus incidences to the changing climate: the mast connection. Int J Health Geogr. 2009;8:1. [Medline].

  4. Bruno P, Hassell LH, Brown J, et al. The protean manifestations of hemorrhagic fever with renal syndrome. A retrospective review of 26 cases from Korea. Ann Intern Med. Sep 1 1990;113(5):385-91. [Medline].

  5. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. Dec 1991;164(6):1119-27. [Medline].

  6. Jovanovic D, Kovacevic Z, Dragovic T, Petrovic M, Tadic J. [Anterior pituitary lobe atrophy as late complication of hemorrhagic fever with renal syndrome]. Vojnosanit Pregl. Feb 2009;66(2):166-8. [Medline].

  7. Al-Hazmi M, Ayoola EA, Abdurahman M, et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis. Feb 1 2003;36(3):245-52. [Medline].

  8. Boonpucknavig V, Soontornniyomkij V. Pathology of renal diseases in the tropics. Semin Nephrol. Jan 2003;23(1):88-106. [Medline].

  9. Doyle TJ, Bryan RT, Peters CJ. Viral hemorrhagic fevers and hantavirus infections in the Americas. Infect Dis Clin North Am. Mar 1998;12(1):95-110. [Medline].

  10. Eboriadou M, Kalevrosoglou I, Varlamis G, et al. Hantavirus nephropathy in a child. Nephrol Dial Transplant. Apr 1999;14(4):1040-1. [Medline].

  11. Elisaf M, Korakis H, Siamopoulos KC. Chronic renal dysfunction in hemorrhagic fever with renal syndrome patients. Ren Fail. 1993;15(5):623-7. [Medline].

  12. Elisaf MS, Siamopoulos KC. Hemorrhagic fever with renal syndrome induced chronic renal dysfunction. Am J Nephrol. 1999;19(6):709. [Medline].

  13. Glass GE, Watson AJ, LeDuc JW, et al. Infection with a ratborne hantavirus in US residents is consistently associated with hypertensive renal disease. J Infect Dis. Mar 1993;167(3):614-20. [Medline].

  14. Golovljova I, Vasilenko V, Mittzenkov V, et al. Characterization of hemorrhagic fever with renal syndrome caused by hantaviruses, Estonia. Emerg Infect Dis. Nov 2007;13(11):1773-6. [Medline].

  15. Kim YK, Lee SC, Kim C, Heo ST, Choi C, Kim JM. Clinical and laboratory predictors of oliguric renal failure in haemorrhagic fever with renal syndrome caused by Hantaan virus. J Infect. Apr 2007;54(4):381-6. [Medline].

  16. Ko KW. Clinical quiz. Haemorrhagic fever with renal syndrome (HFRS, Korean haemorrhagic fever). Pediatr Nephrol. Oct 1995;9(5):537-8. [Medline].

  17. Lautala P, Uhari M. Epidemic nephropathy in children. Am J Dis Child. Oct 1991;145(10):1181-3. [Medline].

  18. Magill AJ. Fever in the returned traveler. Infect Dis Clin North Am. Jun 1998;12(2):445-69. [Medline].

  19. Makela S, Ala-Houhala I, Mustonen J, et al. Renal function and blood pressure five years after puumala virus-induced nephropathy. Kidney Int. Oct 2000;58(4):1711-8. [Medline].

  20. Mustonen J, Vaheri A, Clement J. Third International Conference on Haemorrhagic Fever with Renal Syndrome (HFRS) and Hantaviruses. Nephrol Dial Transplant. Apr 1996;11(4):730-3. [Medline].

  21. Niklasson BS. Haemorrhagic fever with renal syndrome, virological and epidemiological aspects. Pediatr Nephrol. Mar 1992;6(2):201-4. [Medline].

  22. Papadimitriou M. Hantavirus nephropathy. Kidney Int. Sep 1995;48(3):887-902. [Medline].

  23. Papadimitriou MG, Antoniadis A. Hantavirus nephropathy in Greece. Lancet. Apr 23 1994;343(8904):1038. [Medline].

  24. Peco-Antic A, Popovic-Rolovic M, Gligic A, et al. Clinical characteristics of haemorrhagic fever with renal syndrome in children. Pediatr Nephrol. Jul 1992;6(4):335-8. [Medline].

  25. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 1999;50:531-45. [Medline].

  26. Rasche FM, Uhel B, Kruger DH, et al. Thrombocytopenia and acute renal failure in Puumala hantavirus infections. Emerg Infect Dis. Aug 2004;10(8):1420-5. [Medline].

  27. Yoo KH, Choi Y. Haemorrhagic fever with renal syndrome in Korean children. Korean Society of Pediatric Nephrology. Pediatr Nephrol. Oct 1994;8(5):540-4. [Medline].

  28. Zeier M, Handermann M, Bahr U, et al. New ecological aspects of hantavirus infection: a change of a paradigm anda challenge of prevention--a review. Virus Genes. Mar 2005;30(2):157-80. [Medline].

 
Previous
Next
 
Distribution of Hantavirus pulmonary syndrome cases in the United States by virus type. Courtesy of the Centers for Disease Control and Prevention.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.